Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy

Translational Oncology

Volumn 3, Issue 1, 2010, Pages 43-49

  Schmidt, Nils Ole ^a   Ziu, Mateo ^b   Cargioli, Theresa ^c   Westphal, Manfred ^a   Giese, Alf ^d   Black, Peter M ^c   Carroll, Rona S ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; FUREGRELATE; THROMBOXANE SYNTHASE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SURVIVAL TIME; TUMOR GROWTH;

EID: 77953372654     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09238     Document Type: Article

References (34)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, and Reulen HJ (2006). Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7, 392-401.
3. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, et al. (2007). Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25, 2295-2305.
4. Westphal M and Lamszus K (2009). Other experimental therapies for glioma. Recent Results Cancer Res 171, 155-164.
5. Mathieu V, De Neve N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, and Lefranc F (2008). Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383-1392.
6. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K, and Nukiwa T (2002). Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62, 63-66.
7. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, Yamamoto H, Van Meir EG, Deppert W, and Giese A (2003). Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 22, 7716-7727.
8. Nanji AA (1993). Thromboxane synthase and organ preference for metastases. N Engl J Med 329, 138-139.
9. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, and Watson DK (2008). Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 27, 55-62.
10. Dogne JM, de Leval X, Delarge J, David JL, and Masereel B (2000). New trends in thromboxane and prostacyclin modulators. Curr Med Chem 7, 609-628.
11. Kurzel F, Hagel Ch, Zapf S, Meissner H, Westphal M, and Giese A (2002). Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurochir ( Wien) 144, 71-87.
12. Giese A, Hagel C, Kim EL, Zapf S, Djawaheri J, Berens ME, and Westphal M (1999). Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro Oncol 1, 3-13.
13. McDonough W, Tran N, Giese A, Norman SA, and Berens ME (1998). Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. J Neuropathol Exp Neurol 57, 449-455.
14. Yoshizato K, Zapf S, Westphal M, Berens ME, and Giese A (2002). Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells. Neurosurgery 50, 343-354.
15. Schauff AK, Kim EL, Leppert J, Nadrowitz R, Wuestenberg R, Brockmann MA, and Giese A (2009). Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to γ-radiation. J Neurooncol 91, 241-249.
16. Schmidt NO, Ziu M, Carrabba G, Giussani C, Bello L, Sun Y, Schmidt K, Albert M, Black PM, and Carroll RS (2004). Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 10, 1255-1262.
17. 6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther 315, 1247-1255.
18. Schmidt KF, Ziu M, Schmidt NO, Vaghasia P, Cargioli TG, Doshi S, Albert MS, Black PM, Carroll RS, and Sun Y (2004). Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J Neurooncol 68, 207-215.
19. Leon SP, Folkerth RD, and Black PM (1996). Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77, 362-372.
20. Black PM (1991). Brain tumors. Part 1. N Engl J Med 324, 1471-1476.
21. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, and Ram Z (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5, 79-88.
22. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, and Brem H (2008). Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15, 2887-2893.
23. Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, and Mikkelsen T (2008). FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-κB signaling pathway. Neoplasia 10, 235-243.
24. Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, Ghoneim MA, and Watson DK (2005). Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res 65, 11581-11587.
25. Nie D, Che M, Zacharek A, Qiao Y, Li L, Li X, Lamberti M, Tang K, Cai Y, Guo Y, et al. (2004). Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motility. Am J Pathol 164, 429-439.
26. 2. FEBS Lett 580, 3368-3374.
27. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, and Honn KV (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267, 245-251.
28. Jantke J, Ladehoff M, Kurzel F, Zapf S, Kim E, and Giese A (2004). Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 146, 483-494.
29. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, and Lamszus K (1999). Levels of vascular endothelial growth factor, hepatocyte growth factor/ scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84, 10-18.
30. Tassoni D, Kaur G, Weisinger RS, and Sinclair AJ (2008). The role of eicosanoids in the brain. Asia Pac J Clin Nutr 17 (Suppl 1), 220-228.
31. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, and Lamszus K (2008). Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27, 2897-2909.
32. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, Seyfried NT, Abe T, Chen LB, Carroll RS, et al. (2000). Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60, 4926-4931.
33. Mohrland JS, Vander Lugt JT, Gorman RR, and Lakings DB (1989). Thromboxane synthase activity and platelet function after furegrelate administration in man. J Clin Pharmacol 29, 53-58.
34. Mohrland JS, Vander Lugt JT, and Lakings DB (1990). Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects. Eur J Clin Pharmacol 38, 485-488.